Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Evidence: Cefiderocol Therapeutic Drug Monitoring in Critically Ill, Obese Patients with <i>Klebsiella pneumoniae</i> Infections.

Antibiotics (Basel, Switzerland)·2026
Same author

Decoding Immune Dysregulation in Sepsis Through Extracellular Vesicles: A Path to Precision Medicine.

Pharmaceutics·2026
Same author

Retrospective Analysis of the Epidemiology and Risk Factors for Recurrent Biliary-Source Bloodstream Infections in Oncologic Patients.

Antibiotics (Basel, Switzerland)·2026
Same author

Immunosuppressive treatment in solid organ transplant critically ill patients: still an unanswered question?

Intensive care medicine·2026
Same author

Extracellular Vesicle-Derived MicroRNAs' Value in Diagnosing and Predicting Clinical Outcomes in Patients with COVID-19 and Bacterial Sepsis.

International journal of molecular sciences·2026
Same author

Predicting health-related quality of life for patients with gastroesophageal cancer.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026

Related Experiment Video

Updated: Jul 25, 2025

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.1K

Development and Validation of a Prognostic Model for Multi-Drug-Resistant Non-Hospital-Acquired Bloodstream

Emanuele Pivetta1, Silvia Corcione2, Paolo Peasso3

  • 1Department of Medical Sciences, Division of Emergency Medicine and High Dependency Unit, University of Turin, 10126 Turin, Italy.

Antibiotics (Basel, Switzerland)
|June 28, 2023
PubMed
Summary

A new model helps predict multidrug-resistant (MDR) bloodstream infections (BSI) in non-hospital-acquired cases. This tool aids in targeting antibiotic therapy for admitted patients, improving treatment strategies.

Keywords:
bloodstream infectionhealthcare associated bacteremiamultidrug resistanceprognostic models

More Related Videos

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model
07:39

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Published on: April 6, 2021

3.5K
One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures
08:30

One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures

Published on: July 9, 2012

25.6K

Related Experiment Videos

Last Updated: Jul 25, 2025

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.1K
Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model
07:39

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Published on: April 6, 2021

3.5K
One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures
08:30

One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures

Published on: July 9, 2012

25.6K

Area of Science:

  • Infectious Diseases
  • Clinical Microbiology
  • Epidemiology

Background:

  • Bloodstream infections (BSI) are a growing concern in hospital admissions.
  • Distinguishing community-acquired from healthcare-associated (HCA) BSI is crucial due to differing risks of multidrug resistance (MDR).
  • Accurate identification of MDR non-hospital-acquired (non-HA) BSI is essential for effective treatment.

Purpose of the Study:

  • To develop and validate a simple, rapid prognostic model to identify MDR non-HA BSI.
  • To create a tool that can be temporally and spatially validated across different cohorts.
  • To improve the targeting of antibiotic therapy for non-HA BSI.

Main Methods:

  • Retrospective study across three distinct cohorts.
  • Development of a prognostic model incorporating patient demographics and clinical factors.
  • Validation of the model's performance using a C-index.

Main Results:

  • The model includes factors such as age, gender, facility admission, immunocompromise, invasive procedures, central line placement, and recent treatments.
  • The prognostic model demonstrated acceptable performance with a C-index of 70%, particularly for intermediate MDR probabilities.
  • A nomogram was developed to facilitate the application of the model.

Conclusions:

  • The developed prognostic model offers a promising approach for identifying MDR non-HA BSI.
  • The nomogram can aid clinicians in better targeting antibiotic therapy for non-HA BSI.
  • Further validation in diverse populations is recommended to confirm the model's broader applicability.